Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis

被引:27
作者
Martin, Natasha K. [1 ]
Jansen, Klaus [2 ]
an der Heiden, Matthias [2 ]
Boesecke, Christoph [3 ]
Boyd, Anders [4 ,5 ]
Schewe, Knud [6 ]
Baumgarten, Axel [7 ]
Lutz, Thomas [8 ]
Christensen, Stefan [9 ]
Thielen, Alexander [10 ]
Mauss, Stefan [11 ]
Rockstroh, Juergen K. [3 ]
Skaathun, Britt [1 ]
Ingiliz, Patrick [7 ,12 ]
机构
[1] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, San Diego, CA 92103 USA
[2] Robert Koch Inst, Berlin, Germany
[3] Univ Bonn, Dept Med, Bonn, Germany
[4] INSERM, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France
[5] Publ Hlth Serv Amsterdam, Dept Infect Dis Res & Prevent, Amsterdam, Netherlands
[6] Infekt Med Ctr Hamburg, Hamburg, Germany
[7] Ctr Infectiol, Berlin, Germany
[8] Infektiologikum, Frankfurt, Germany
[9] Ctr Innere Med, Munster, Germany
[10] Inst Immunol & Genet, Kaiserslautern, Germany
[11] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[12] Charite Univ Med Ctr Berlin, Dept Hepatol & Gastroenterol, Berlin, Germany
关键词
hepatitis C virus; HCV; prevention; elimination; modeling; HIV-POSITIVE MEN; INJECT DRUGS; ANTIVIRAL TREATMENT; HCV TRANSMISSION; LIFE EXPECTANCY; PEOPLE; PREVENTION; IMPACT; INTERVENTIONS; COINFECTION;
D O I
10.1093/infdis/jiz367
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Despite high hepatitis C virus (HCV) treatment rates, HCV incidence among human immunodeficiency virus (HIV)-infected men who have sex with men (HIV-infected MSM) in Germany rose before HCV direct-acting antivirals (DAAs). We model what intervention can achieve the World Health Organization (WHO) elimination target of an 80% reduction in HCV incidence by 2030 among HIV-infected MSM in Berlin. Methods: An HCV transmission model among HIV-diagnosed MSM was calibrated to Berlin (rising HCV incidence and high rates of HCV testing and treatment). We modeled the HCV incidence among HIV-diagnosed MSM in Berlin until 2030 (relative to 2015 WHO baseline) under scenarios of DAA scale-up with or without behavior change (among HIV-diagnosed MSM and/or all MSM). Results: Continuing current treatment rates will marginally reduce the HCV incidence among HIV-diagnosed MSM in Berlin by 2030. Scaling up DAA treatment rates, beginning in 2018, to 100% of newly diagnosed HCV infections within 3 months of diagnosis and 25% each year of previously diagnosed and untreated HCV infections could reduce the HCV incidence by 61% (95% confidence interval, 55.4%-66.7%) by 2030. The WHO target would likely be achieved by combining DAA scale-up with a 40% reduction in HCV transmission among HIV-diagnosed MSM and a 20% reduction among HIV-undiagnosed or HIV-uninfected MSM. Discussion: HCV elimination among HIV-infected MSM in Berlin likely requires combining DAA scale-up with moderately effective behavioral interventions to reduce risk among all MSM.
引用
收藏
页码:1635 / 1644
页数:10
相关论文
共 48 条
[1]  
[Anonymous], 2018, LANCET HIV, V5, pE605, DOI 10.1016/S2352-3018(18)30299-6
[2]  
[Anonymous], EMIS 2010 EUR MEN WH, DOI DOI 10.2900/79639
[3]  
[Anonymous], CROI C
[4]  
[Anonymous], EPID B
[5]  
[Anonymous], 2014, HIV UK 2014 REPORT D
[6]   Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study [J].
Blach, Sarah ;
Zeuzem, Stefan ;
Manns, Michael ;
Altraif, Ibrahim ;
Duberg, Ann-Sofi ;
Muljono, David H. ;
Waked, Imam ;
Alavian, Seyed M. ;
Lee, Mei-Hsuan ;
Negro, Francesco ;
Abaalkhail, Faisal ;
Abdou, Ahmed ;
Abdulla, Maheeba ;
Abou Rached, Antoine ;
Aho, Inka ;
Akarca, Ulus ;
Al Ghazzawi, Imad ;
Al Kaabi, Saad ;
Al Lawati, Faryal ;
Al Namaani, Khalid ;
Al Serkal, Youssif ;
Al-Busafi, Said A. ;
Al-Dabal, Layla ;
Aleman, Soo ;
Alghamdi, Abdullah S. ;
Aljumah, Abdulrahman A. ;
Al-Romaihi, Hamad E. ;
Andersson, Monique I. ;
Arendt, Vic ;
Arkkila, Perttu ;
Assiri, Abdullah M. ;
Baatarkhuu, Oidov ;
Bane, Abate ;
Ben-Ari, Ziv ;
Bergin, Colm ;
Bessone, Fernando ;
Bihl, Florian ;
Bizri, Abdul R. ;
Blachier, Martin ;
Blasco, Antonio J. ;
Mello, Carlos E. Brandao ;
Bruggmann, Philip ;
Brunton, Cheryl R. ;
Calinas, Filipe ;
Chan, Henry L. Y. ;
Chaudhry, Asad ;
Cheinquer, Hugo ;
Chen, Chien-Jen ;
Chien, Rong-Nan ;
Choi, Moon Seok .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03) :161-176
[7]   Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy [J].
Boerekamps, Anne ;
van den Berk, Guido E. ;
Lauw, Fanny N. ;
Leyten, Eliane M. ;
van Kasteren, Marjo E. ;
van Eeden, Arne ;
Posthouwer, Dirk ;
Claassen, Mark A. ;
Dofferhoff, Anton S. ;
Verhagen, Dominique W. M. ;
Bierman, Wouter F. ;
Lettinga, Kamilla D. ;
Kroon, Frank P. ;
Delsing, Corine E. ;
Groeneveld, Paul H. ;
Soetekouw, Robert ;
Peters, Edgar J. ;
Hullegie, Sebastiaan J. ;
Popping, Stephanie ;
van de Vijver, David A. M. C. ;
Boucher, Charles A. ;
Arends, Joop E. ;
Rijnders, Bart J. .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (09) :1360-1365
[8]   Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome [J].
Boesecke, Christoph ;
Ingiliz, Patrick ;
Reiberger, Thomas ;
Stellbrink, Hans-Juergen ;
Bhagani, Sanjay ;
Page, Emma ;
Mauss, Stefan ;
Lutz, Thomas ;
Voigt, Esther ;
Guiguet, Marguerite ;
Valantin, Marc-Antoine ;
Baumgarten, Axel ;
Nelson, Mark ;
Vogel, Martin ;
Rockstroh, Jurgen K. .
INFECTION, 2016, 44 (01) :93-101
[9]   Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men? [J].
Boettiger, David C. ;
Salazar-Vizcaya, Luisa ;
Dore, Gregory J. ;
Gray, Richard T. ;
Law, Matthew G. ;
Callander, Denton ;
Lea, Toby ;
Rauch, Andri ;
Matthews, Gail, V .
CLINICAL INFECTIOUS DISEASES, 2020, 70 (01) :106-113
[10]   Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men [J].
Charre, Caroline ;
Cotte, Laurent ;
Kramer, Rolf ;
Miailhes, Patrick ;
Godinot, Matthieu ;
Koffi, Joseph ;
Scholtes, Caroline ;
Ramiere, Christophe .
PLOS ONE, 2018, 13 (01)